Monopar Therapeutics Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2016 | -41.9% | -41.9% | -40.9% |
| FY2017 | -172.1% | -172.1% | -166.7% |
| FY2018 | -46.7% | -46.7% | -44.1% |
| FY2019 | -33.5% | -33.5% | -31.6% |
| FY2020 | -40.2% | -40.2% | -37.4% |
| FY2021 | -48.1% | -48.1% | -44.4% |
| FY2022 | -104.2% | -104.2% | -79.5% |
| FY2023 | -150.4% | -150.4% | -114.4% |
| FY2024 | -28.3% | -28.3% | -25.9% |
| FY2025 | -10.0% | -10.0% | -9.7% |